The publisher explores Pfizer’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
Model updates (2 March 2020)
Model updates (5 November 2019)
Model updates (16 August 2019)
Snapshot
- Overview: Pfizer’s overall sales will decline due to the spin-off of Upjohn and the sale of its Consumer Healthcare division, but Pfizer’s core Biopharma division will see growth over the medium term.
- Key themes: [1] A slimmed-down Pfizer will see growth over the medium term, but patent expirations for key franchises – Eliquis, Xeljanz, Prevnar, and Ibrance – will negatively impact growth over the forecast period [2] Business development activities remain a high priority, both additive, like Array BioPharma, and pruning, like Upjohn and the Consumer Healthcare portfolio [3] Pfizer’s potential drug launches will not offset declines from the company’s approved drugs.
Model updates (2 March 2020)
- Alliance revenue forecast adjusted higher due to strong growth of Eliquis in non-valvular atrial fibrillation, as well as NOAC market share gains
- Ibrance forecast adjusted higher due to continued CDK class market share growth in the US and continued strong uptake following launches in emerging markets
- Prevnar forecast adjusted higher due to continued pediatric uptake in China
- Vyndaqel forecast adjusted higher due to strong launch in the US and continued uptake in Europe and Japan
- Tanezumab forecast pulled forward due to regulatory timeline in the US
- Braftovi/Mektovi forecast incorporated after closing of Array acquisition.
Model updates (5 November 2019)
- Sutent forecast adjusted lower in the US and 5EU due to sales declines
- Inlyta forecast adjusted higher due to rapid adoption after approvals for first-line treatment of renal cell cancer in combination with Keytruda and Bavencio
- Inflectra/Remsima forecast lowered due to competition in Europe
- Vyndaqel forecast adjusted higher due to strong launch in the US and continued uptake in Europe and Japan
- Retacrit forecast added
- Braftovi/Mektovi forecast added due to Pfizer closing acquisition of Array BioPharma.
Model updates (16 August 2019)
- Alliance revenue (primarily Eliquis) forecast adjusted higher due to continued adoption in non-valvular atrial fibrillation and market share gains within the oral anti-coagulant market
- Ibrance forecast adjusted higher due to continued market share gains internationally
- Xeljanz forecast adjusted lower due to recent product label changes
- Vyndaqel forecast adjusted higher to account for global launches
- Eucrisa forecast added for the five major EU markets and Rest of World, and adjusted lower for the US
- Abrocitinib forecast added
- Tanezumab forecast added
- Daurismo forecast added
- PF-06838435 forecast added
- Lyrica forecast removed after mid-2020 due to Upjohn combination with Mylan
- Lipitor forecast removed after mid-2020 due to Upjohn combination with Mylan
- Norvasc forecast removed after mid-2020 due to Upjohn combination with Mylan
- Celebrex forecast removed after mid-2020 due to Upjohn combination with Mylan
- Viagra forecast removed after mid-2020 due to Upjohn combination with Mylan
- Effexor forecast removed after mid-2020 due to Upjohn combination with Mylan
- Zoloft forecast removed after mid-2020 due to Upjohn combination with Mylan
- Xalatan forecast removed after mid-2020 due to Upjohn combination with Mylan
- Revatio forecast removed after mid-2020 due to Upjohn combination with Mylan
- Xanax forecast removed after mid-2020 due to Upjohn combination with Mylan
- Updated non-pharmaceutical revenue to account for closing of PFE and GSK Consumer Healthcare Joint Venture; given ownership structure PFE will only report its profit share.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
